Five hundred and eight cases of early synovectomy of the knee in rheumatoid arthritis are reported from nine clinics in a retrospective multi-center follow-up study. Observation time covers at least ten years in each case. Sixty-five per cent of the cases are reported as being subjectively and objectively good. The mean roentgenological grade, according to Larsen, was 1.7 preoperatively and 2.7 at follow-up.
The purpose of this study was to develop complex diagnostic and corrective measures during pregnancy in women with undifferentiated connective tissue dysplasia. Material and Subjects: the research object was 380 women who were treated in Tula regional perinatal centre and Maternity hospital №1 of Tula with signs of undifferentiated connective tissue dysplasia during 2008- 2010 yy., and as a comparison group 45 women in the absence of signs of dysplasia in the same time period. To assess the magnesium therapy effectiveness, the women of experimental group were divided into two subgroups (190+190) depending on the use/non-use of the preparation of magnesium with early pregnancy term. Results: undifferentiated connective tissue dysplasia during pregnancy is clinically manifested by neurocirculatory dystonia, vascular disorders and hemorrhagic syndrome, as well as a high frequency of placenta insufficiency, threatened abortion in 1-3 trimesters, isthmic-cervical insufficiency, early toxicosis and anemia of pregnant. The etiological-pathogenetical treatment was resulted in to the improvement of pregnant women health, reduction of the frequency of different complaints and decreased of average weight of these pregnancy complications. Normalization of parameters of oxyproline and magnesium in the blood of pregnant women in 12-22-34 weeks of pregnancy due to magnesium therapy was laboratory confirmed. Conclusion: undifferentiated connective tissue dysplasia during pregnancy contributes to the development of certain pathological conditions of various systems of the body and it can be effectively corrected by magnesium drugs (Magne-B6) under the control of oxyproline and magnesium in the blood of pregnant women. Magnesium therapy ensures the accessibility, quality and efficiency of health prevention activities to women with undifferentiated connective tissue dysplasia that has a significant impact on the effectiveness of antenatal preparation and enhances the quality of life of pregnant women.
Aim: a comprehensive study of the pathology manifestations and efficiency of magnesium therapy in pregnant women with undifferentiated connective tissue dysplasia. Material and Subjects: the research object was 380 women who were treated in Tula regional perinatal centre and Maternity hospital №1 of Tula with signs of undifferentiated connective tissue dysplasia during 2008-2010 yy., and as a comparison group 45 women in the absence of signs of dysplasia in the same time period. To assess the magnesium therapy effectiveness of the women experimental group they were divided into two subgroups (190+190) depending on the use/non-use of the preparation of magnesium with early pregnancy term. Results: undifferentiated connective tissue dysplasia during pregnancy was clinically manifested by neurocirculatory dystonia, vascular disorders and hemorrhagic syndrome, as well as a high frequency of placenta insufficiency, threatened abortion in 1-3 trimesters, isthmic-cervical insufficiency, early toxicosis and anemia of pregnant. The etiological-pathogenetical treatment was resulted in to the improvement of pregnant women health, reduction of the frequency of different complaints and decreased of average weight of these pregnancy complications. Normalization of parameters of oxyproline and magnesium in the blood of pregnant women in 12-22-34 weeks of pregnancy due to magnesium therapy was laboratory confirmed. Conclusion: undifferentiated connective tissue dysplasia during pregnancy contributes to the development of certain pathological conditions of various systems of the body and it can be effectively corrected by magnesium drugs (Magne-B6) under the control of oxyproline and magnesium in the blood of pregnant women.
Aim: a comparison of the mifepristone in different doses effectiveness to prepare the cervix of uterus for delivery with its unsatisfactory "ripening" in 37-41 weeks pregnancy. Material and Subjects: the object of a continuous prospective study were 205 women who delivered babies in Maternity hospital №1 of town Tula for 2010-2011 yy with unsatisfactory "ripening" of the cervix at term pregnancy. Study groups was formed by a dosage of using the medical drug to prepare the cervix of uterus for delivery. Group IA was consisted of 177 pregnant women who received mifepristone peroral by a standard scheme, the group IB - 28 pregnant women who received mifepristone by the minimized scheme of the drug. The cervix of uterus readiness for childbirth was assessed by vaginal examination in accordance with the scale E.H. Bishop. Results: after medical treating by mifepristone "not ready enough" cervix of uterus were received the same results in both groups. The cervix of uterus condition improved to full readiness to 82,7% in IA and 83,3% cases in the IB group (OR=0,96; 95% CI of 0,23 to 4,0). In patients who initially had an "unripe" cervix of uterus after administration of mifepristone was noted significant improvement in her condition, - in group IA 66,4% of women had "ripe" cervix, in 24,8% were "not ripe enough" and 8,8% remained "unripe". In the IB group were obtained almost similar results: 60,0%, 30,0% and 10,0% respectively (p>0,05). It was´t found significant differences between groups in aspects of the delivery and the health status of newborns. Conclusion: the efficacy of mifepristone using in a dose of 200 mg 2 times with an interval of 24 hours to prepare the cervix of uterus for delivery is similar with the use of this drug in a dose of 100 mg 2 times with an interval of 24 hours for "not ripe enough" and acceptable for "unripe" cervix condition at 37-41 weeks of gestation. Pregnant women with a necessary the cervix of uterus preparation for to optimize hospital care perhaps the use of mifepristone in the outpatient setting for 3 days prior to hospitalization for childbirth.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.